Biotech firm Odyssey targets $810 million in valuation in US IPO
May 4 (Reuters) – Biopharmaceutical company Odyssey Therapeutics said on Monday it is targeting a valuation of up to $809.9 million in its initial public offering in the United States. The company is seeking to raise up to $238.3 million by offering 13.2 million shares priced between $16 and $18 apiece. The U.S. IPO market is showing early signs of reopening, with April marking the busiest month for new filings […]